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Neuropeptides make up one of the largest and func­
tionally most diverse groups of signaling molecules. 
They exert their effects by interacting with members 
of the large family of G-protein-coupled receptors, 
which transmit information about the extracellular 
environment to the interior of the cell by interacting 
with the heterotrimeric G-proteins. Cellular re­
sponses to neuropeptides are usually rapidly attenu­
ated. Mechanisms of signal attenuation include re­
moval of peptides from the extracellular fluid and 
receptor desensitization. Peptides are removed from 
the extracellular fluid principally by enzYlDatic deg­
radation by cell surface enZYIDes. exemplifi.ed by 
neutral endopeptidase. Receptor desensitization is 
mediated by l'eceptor phosphorylation by G-protein 
receptor kinases and second messenger kinases. in­
teraction of receptors with arrestins. and consequent 
receptor uncoupling from G-proteins. Peptides also 
Regulatory peptides make up one of the largest and functionally most diverse groups of signaling mol­ecules. They are released from endocrine cells, paracrine cells, and central and peripheral neurons, and regulate target cells by interacting with mem­
bers of the superfamily of G-protein-coupled receptors (Watson 
and Arkinstall, 1994). Comparison of the primary structure of these 
receptors reveals several major shared characteristics: they all have 
seven sequences of 20-25 hydrophobic residues that form an 
a-helix and are believed to span the plasma membrane, an extra­
cellular N terminus, three extracellular loops, three intracellular 
loops, and an intracellular C-tail. Their principal function is to 
transmit information about the extracellular environment to the 
interior of the cell, and they do so by interacting with the 
heterotrimeric G-proteins. Thus, neuropeptides and their receptors 
are involved in many aspects of normal regulation, including 
control of cell growth and proliferation, secretion, and motility and 
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Abbreviations: SP, substance P; NKA, neurokinin A; NKB, neurokinin B; 
BK, bradykinin; NK1-R, neurokinin 1 receptor; NEP, neutral endopepti­
dase; GRK, G-protein receptor kinase. 
induce endocytosis of their receptors, which may 
contribute to desensitization by depleting the cell 
surface of high-affinity receptors. Recycling and pro­
cessing of internalized receptors. which include· dis­
sociation of receptors from their ligands and receptor 
dephosphorylation. contribute to resensitization of 
cellular responses. These regulatory mechanisms are 
important for they determine the ability of cells to 
respond to agonists. and defects may result in uncon­
trolled stimulation of cells, which could cause dis­
ease. A greater understanding of the processes that 
modulate signaling by neuropeptides may lead to the 
development of novel receptor antagonists and ago­
nists and help to explain the mechanism of drug 
tolerance. Key words: neuropeptidaseslreceptor downregu­
lationIG-protein-coupkd receptors. Journal of Investigative 
Dermatology Symposium Proceedings 2:69-75, 1997 
may also participate in control of pathophysiologic states, such as 
infiammation. 
Cellular responses to neuropeptides are often rapidly attenuated. 
In common with many important biologic processes, there are 
multiple mechanisms of attenuation and considerable apparent 
redundancy (see Bohm et aI, 1997, for review). Thus, attenuation of 
signaling may involve removal of the peptide from the extracellular 
fluid, chemical modification of the activated receptor and subse­
quent uncoupling from G-proteins, agonist-induced receptor en­
docytosis to deplete the cell surface of agonist binding sites, 
regulation of levels of receptor expression, as well as modification 
of numerous downstream events that may affect G-proteins and 
second messengers (Hausdorff et aI, 1990; Lohse, 1993). A discus­
sion of all of these possible mechanisms of attenuation is beyond the 
scope of this brief review. Instead, the review will focus on 
mechanisms of attenuation that operate at the level of the agonist 
and the receptor. In particular we will discuss mechanisms that 
remove peptides from the extracellular fiuid and that determine the 
ability of the receptor to interact with agonists and with G-proteins 
(Fig 1). This is not an exhaustive review of the literature concerning 
attenuation of signaling by all neuropeptides. Rather, it will 
concentrate on mechanisms that regulate cellular responses to the 
tachykinin family of neuropeptides, although references will be 
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Figure 1. Mechanisms that attenuate signaling by neuropeptide 
receptors. (A) Enzymatic degradation of the peptide is the first step in 
tenninating the signal. (B) Phosphorylation of activated receptors by GRKs 
and subsequent interaction of the receptor with arrestins interdicts interac­
tions with G-proteins and effectively tenninates the signal causing rapid 
desensitization. (C) Agonist-induced endocytosis depletes the plasma mem­
brane of high-affinity receptors and may represent a second phase of 
desensitization. Internalization, dissociation of receptor and agonist in 
acidified endosomes, receptor dephosphorylation and dissociation of ar­
restins, and receptor recycling are required for resensitization. 
made to other peptides and their receptors where our knowledge is 
more complete. 
TACHYKININS AND NEUROKININ RECEPTORS 
In many ways the tachykinin family of peptides and their associated 
receptors are prototypical of the regulatory peptides [see Otsuka 
and Yoshioka (1993) for review]. Substance P (SP) was one of the 
first neuropeptides to be identified. It was discovered in 1931 by 
von Euler and Gaddum when they identified an activity in extracts 
prepared from the brain and intestine of the horse that induced 
atropine-resistant contraction of rabbit jejunum and caused hypo­
tension (von Euler and Gaddum, 1931). They named the activity 
substance or preparation P (for powder, the form of their crude 
extract) and were the first to identify a peptide both in the brain and 
gastrointestinal tract. SP was isolated and characterized as an 
ll-amino acid peptide in 1970 by Leeman and colleagues. In the 
1980s several groups reported the isolation of two other mamma­
lian tachykinins, neurokinin A, (NKA, also called neurokinin a, 
substance K, and neuromedin L) and neurokinin B (NKB, also 
known as neurokinin (3 or neuromedin K). All of the tachykinin 
peptides share the C-terminal sequence of Phe-X-Gly-Leu-Met 
NH2• The preprotachykinin genes were some of the first genes 
encoding peptides to be characterized. In mammals, two genes 
encode the tachykinins. The preprotachykinin I gene encodes SP 
and NKA. Alternative splicing and transcription of the preprotachy­
kinin I gene produce three different mRNA species that contain the 
sequence encoding either SP and NKA «(3-preprotachykinin and 
-y-preprotachykinin) or SP alone (a-preprotachykinin). The prepro­
tachykinin II gene encodes NKB but not SP or NKA. 
JID SYMPOSIUM PROCEEDINGS 
Receptors for these pep tides were also some of the first to be 
identified and subsequently cloned (Otsuka and Yoshioka, 1993). 
There are three neurokinin receptors (NK-R), and each tachykinin 
interacts with all three receptors, albeit with graded affinity: 
NKl-R - SP>NKA>NKB; NK2-R - NKA>NKB>SP; NK3-
R - NKB>NKA>SP. The tachykinins exert their multiple and 
widespread biologic actions by interacting with these receptors. 
They function as neurotransmitters in the peripheral and central 
nervous systems, stimulate smooth muscle contraction and exocrine 
secretion, and mediate neurogenic inflammation. Thus, the tachy­
kinins and their receptors participate in multiple physiologic control 
mechanisms and are also involved in pathophysiologic conditions 
such as transmission of information from pain receptors and inflam­
mation. Many of these biologic effects are rapidly attenuated by 
peptide degradation and receptor desensitization. 
PEPTIDE DEGRADATION BY CELL-SURFACE 
PEPTIDASES 
Removal of neurotransmitters from extracellular fluid is the earliest 
mechanism of attenuation. Three processes contribute to this 
removal: dilution, re-uptake, and degradation. All neurotransmit­
ters are diluted as they diffuse throughout the extracellular fluid to 
concentrations that are too low to excite target cells. Re-uptake by 
high-affinity transporters efficiently removes the catecholamine and 
amino acid neurotransmitters. Although many peptides are taken 
into cells by endocytosis of their receptors (see Agonist-Induced 
Receptor Endocytosis), this is related to receptor desensitization rather 
than agonist removal. In a manner that is reminiscent of the 
degradation of acetylcholine in synapses by acetylcholinesterase, 
enzymatic degradation is the main mechanism for removal of 
neuropeptides. Both cell-surface and soluble peptidases degrade 
peptides, but neuropeptide degradation by cell surface peptidases 
has been most extensively examined [see Kenny and Hooper 
(1991) for review]. There are several well characterized cell surface 
peptidases that degrade neuropeptides, including aminopeptidases, 
carboxypeptidases, and endopeptidases. They are anchored to the 
plasma membrane and have an active site that projects into the 
extracellular fluid. Thus, they are ideally placed to degrade neu­
ropeptides at the cell surface in the vicinity of their receptors and 
thereby restrict the number of intact peptide molecules that are 
available to interact with receptors and initiate signaling. The 
extensive literature on neuropeptide-degrading peptidases is the 
subject of several current reviews. This review will focus on one 
neuropeptide degrading endopeptidases, neutral endopeptidase 
(NEP, EC 3.4.24.11), also known as endopeptidase-24.11, enkeph­
alinase, CALLA, CD10, and most recently neprilysin [see Roques et 
al (1993) for review]. This enzyme is selected because it has been 
extensively studied and can be regarded as the prototypical neu­
ropeptide-degrading enzyme. 
NEP is one of several peptidases that was originally identified in 
the brush border of the kidney and subsequently purified from 
many tissues that are regulated by neuropeptides, including the 
brain, gastrointestinal tract, and lymph nodes. It is expressed by 
multiple cell types, including neurons, epithelial cells, endothelial 
cells, and smooth muscle cells. Molecular cloning identified NEP as 
a protein of 749 residues with an intracellular N-terminal tail of 27 
residues, a single hydrophobic domain of 22 residues that is 
believed to span the plasma membrane, and a large extracellular C 
terminus that contains the active site. The active site, identified by 
site-directed mutagenesis, resembles that of other zinc metalloen­
zymes, including thermolysin and angiotensin-converting enzyme. 
Peptidases are relatively promiscuous because a single enzyme 
will usually degrade several peptides, albeit with graded affinity. 
NEP degrades a variety of biologically active pep tides. Preferred 
residues in the Pl' site are hydrophobic, such as Phe, Leu, Val, Tyr, 
and Tep. Kinetically favorable substrates include the tachykinins, 
opioids, bombesin/ gastrin-releasing peptide family, somatostatin, 
cholecystokinin/gastrin, bradykinin (BK), and atrial natriuretic 
peptides. The affinity of NEP for its substrate peptides, however, is 
far lower than that of receptors for neuropeptides. For example, the 
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Figure 2. The effects of SP (0.1, 0.5, and 1.0 oM added at �) on 
[eaH]. measured using fura-2/AM in KNRK-NK1-R cells, KNRK­
NK1-R-NEP cells, and KNRK-NK1-R-NEP treated with the NEP 
inhibitor thiorphan (1 p.M). The traces show that coexpression of NEP 
abolishes or markedly attenuates SP-induced Ca2+ mobilization. [Repro-
duced from Okamoto et al (1994).] , 
K.n ofNEP for SP is 32 f.LM, which is almost 10,000-fold less than 
the affinity SP interaction with the NK1-R (Kd 3.5 nM) (Matsas et 
aI, 1983, 1984; Hershey and Krause, 1990). 
We examined whether NEP can interdict the interaction of the 
interaction of SP and the NK1-R despite the far higher affinity of SP 
for the NK1-R (Okamoto et aI, 1994). Rat kidney epithelial cells 
(KNRK) were stably transfected with cDNA encoding either the 
NK1-R alone, NEP alone, or both NEP and the NK1-R. To 
determine whether co-expression of NEP in the same cell as the 
NK1-R affected binding, we compared the time course of[12SI]SP 
binding to cells expressing the NK1-R alone (KNRK-NK1-R) and 
cells co-expressing NEP and the NK1-R (KNRK-NK1-R-NEP). 
In KNRK-NK1-R cells, binding at 20 min was 92.2 ± 3.1% of 
maximal. In contrast, binding to KNRK-NK1-R-NEP cells at 20 
min was only 13.9 ± 0.5% of maximal. This was elevated to 82.7 ± 
2.4% of maximal by inhibition of NEP with thiorphan. We 
compared signaling by measuring SP-stimulated Ca2+ mobiliza­
tion. SP induced a prompt increase in [Ca2+]j in KNRK-NK1-R 
cells, with an apparent ECso of 0.66 nM. Co-expression of NEP 
with NK1-R in KNRK-NK1-R-NEP cells abolished to undetect­
able levels the Ca2+ response to 0.3 nM and 0.5 nM SP and 
markedly attenuated the response to 1 nM and 3 nM SP (Fig 2). 
These effects were reversed by thiorphan. Thus, 1 nM SP induced 
an increase in [Ca2+]i in KNRK-NK1-R-NEP cells of 52.3 ± 13.1 
nM in the absence of thiorphan and of 161.4 ± 25.1 nM in the 
presence of thiorphan. In contrast, when cells expressing the 
NKI-R alone were mixed with cells expressing NEP alone, SP 
binding and signaling were minimally affected. 
Despite the far higher affinity of SP for the NK1-R, NEP can 
effectively disrupt signaling provided that it is co-expressed in the 
same cell as the receptor. Thus, NEP must be strategically placed 
and in a high concentration if it is to degrade SP at the cell surface, 
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reduce the concentration of peptide in the vicinity of the NK1-R, 
and thereby attenuate SP signaling. Comparisons of the distribution 
of NEP with that of potential substrates and neuropeptide receptors 
will provide information about the functions of this enzyme. 
The involvement of NEP in terminating the biologic actions of 
neuropeptides has been extensively studied by using selective NEP 
inhibitors. In a manner reminiscent of the effects of eserine on 
cholinergic neurotransmission, NEP inhibitors such as phosphor­
amidon and thiorphan potentiate the biologic actions of neuropep­
tides in many systems (Roques et aI, 1993). Some of the effects of 
NEP inhibitors are especially noteworthy because of their possible 
clinical relevance. For example, inhibitors of NEP and aminopep­
tidase N suppress the degradation of enkephalins and SP in the 
central nervous system where they can have anti-nociceptive 
effects. In the periphery, NEP inhibitors enhance the contractile 
effects of enkephalin, SP, gastrin-releasing peptide, and somatosta­
tin on gastrointestinal smooth muscle (Menozzi et aI, 1991; Gu et aI, 
1992, 1993). 
We recently examined the function of NEP by studying mice in 
which the gene encoding NEP was deleted by homologous recom­
bination (Lu et aI, 1995; Lu et aI, 1997). This permitted investigation 
of the role of NEP without the use of peptidase inhibitors, which 
may have nonspecific effects and which are difficult to administer 
for prolonged periods. We used these animals to assess the role of 
NEP in terminating the pro-inflammatory effects of SP and BK. SP 
released from sensory neurons mediates neurogenic inflammation, 
which is characterized by arteriolar dilatation and extravasation of 
plasma from post-capillary venules. BK generated at sites of 
inflammation also causes vasodilatation and plasma leakage partly 
by releasing SP from afferent neurons. We measured plasma 
extravasation using Evans blue and localized the site of the leak 
with the colloidal tracer Monastral blue. In wild type mice, 
intravenous injections of SP or BK stimulated widespread plasma 
extravasation from post-capillary venules. The response to SP was 
abolished by treatment of mice with a selective antagonist of the 
NKI-R and is thus mediated by the NKI-R. The leak to BK was 
similarly inhibited by a B2-receptor antagonist, indicating that it is 
mediated by the B2-receptor. The NKI-R antagonist also reduced 
the leak to exogenous BK, which is to be expected because BK also 
releases SP from afferent neurons. Remarkably, under unstimulated 
basal conditions, there was markedly elevated plasma extravasation 
in "knockout" mice (2- to 5-fold higher than in wild-type mice) in 
the gastrointestinal tract, pancreas, urinary bladder, airway, and 
skin (Fig 3). This elevated leak was attenuated by injection of 
recombinant NEP and by antagonists of the NKI-R and BK 
B2-receptor. In contrast, the basal leak in wild-type mice was 
stimulated by injection ofNEP inhibitors. Furthermore, the degra­
dation of both SP and BK by membrane preparations is diminished 
in "knockout" compared to wild type mice. Thus, genetic deletion 
or pharmacologic inhibition of NEP results in diminished degrada­
tion of SP and BK, which cause plasma extravasation by interacting 
with NKI-R and B2-receptor, respectively. This suggests that NEP 
not only functions to degrade peptides after stimulated secretion 
but also serves to maintain low basal levels of neuropeptides. These 
findings are of possible clinical interest because NEP is downregu­
lated in inflamed tissues, which may contribute to uncontrolled 
inflammation. Angiotensin-converting enzyme may have similar 
effects to NEP in this regard because we have recently found that 
injection of the inhibitors of this enzyme (captopril and enalapril) to 
wild type mice also causes elevated plasma extravasation, which is 
mediated by diminished degradation of SP and BK (N. W. Bunnett 
and P. Geppetti, unpublished observations). This may be of conse­
quence to patients who receive these drugs. 
MECHANISMS OF RECEPTOR DESENSITIZATION 
Clearly, enzymatic degradation must permit a sufficient number of 
peptide molecules to interact with receptors and regulate cellular 
responses. Thus, degradation probably serves to restrict or confine 
the effects of pep tides to a particular cell type or to a certain region 
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Figure 3. Extravasation of Evans bille 
in the stomach of wild-type [NEP (+1 
+)] and "knockollt" [NEP (-1-)] 
mice. Panel a shows the effects of exoge­
nous SP and BK on basal extravasation of 
Evans blue in NEP (+ / +) mice. SP and BK 
(both 1 nmol'kg-1 i.v.) stimulated extrav­
asation in NEP (+/+) mice (the basal leak 
in NEP ( -/ - ) mice was so high that it was 
minimally affected by exogenous SP or 
BK). SP-induced extravasation was abol­
ished by SR 140333 and was thus mediated 
by the NK1-receptor, whereas HOE 140 
had no effect, confirming the specificity of 
this antagonist. BK-induced extravasation 
was abolished by HOE 140 and was thus 
mediated by the B2-receptor. SR 140333 
also reduced the leak to BI{, which is 
expected because BK stimulates SP release 
from afferent neurons. Panel b shows that 
extravasation was 3- to 4-fold higher in 
NEP (-/-) than in NEP (+1+) mice 
under basal, unstimulated conditions. In 
NEP (+ / +) mice, administration of the 
NEP inhibitors phosphoramidon (phos.) or 
thiorphan (thio.) (both 2.5 mg.kg-l i.v.) 
stimulated extravasation to levels observed 
in NEP ( -/ -) mice under basal condi­
tions. Conversely, the elevated basal ex­
travasation in NEP ( - / -) mice was inhib­
ited by recombinant human NEP (3 
mg-kg-1 i.v). This elevated leak in NEP 
(-/ -) mice was also inhibited by SR 
140333 (1 l£IIlol'kg-l i.v.) and HOE140 
(0.1 nmol'kg-l i.v.), antagonists of the 
NK1- and B2-receptors, respectively. Ex­
travasation is expressed as nanograms of 
Evans blue per mg of dry tissue, mean ± SE 
(n). *, p < 0.05 compared to basal for NEP 
(+/+) mice; t, p < 0.05 compared to basal 
for NEP (- / - ) mice (analysis of variance, 
Bonferroni t test). 
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of the cell. Cellular signals are rapidly attenuated, however, by 
mechanisms that operate at the level of the receptors. 
A common feature of cellular responses to agonists of the 
G-protein- coupled receptors is that they are rapidly (seconds to 
minutes) attenuated even in the continued presence of agonist, and 
repeated challenge with agonist results in a diminution of respon­
siveness. The attenuation of responses in the continued presence of 
agonist and the decline in responses to repeated challenge are 
referred to as desensitization. With time (minutes to hours) cells 
recover their ability to respond to agonists, a phenomenon known 
as resensitization. Continuous exposure of cells to agonists for 
prolonged periods (hours to days) often leads to a long lasting 
decline in receptor content and cellular responsiveness, which is 
referred to as receptor downregulation, and recovery from downregu­
lation is slow (hours to days). Two types of desensitization can be 
distinguished on the basis of the underlying mechanism. Homologous 
desensitization is mediated by agonist-dependent activation of the 
same receptor, whereas heterologous desensitization is caused by 
agonist-independent activation of a dYferent receptor. 
An important component of desensitization, which occurs within 
seconds to minutes of receptor activation, is uncoupling of the 
activated receptor from its G-proteins by receptor phosphorylation 
[see Hausdorff et al (1990); Lohse (1993) for review]. Two classes 
of protein kinases mediate this phosphorylation. A unique class of 
serine/threonine protein kinases, namely the G-protein receptor 
kinases (GRKs) , mediate agonist-dependent phosphorylation of 
G-protein-coupled receptors and initiate homologous desensitiza­
tion. Second messenger-dependent kinases (protein kinase A and 
C) mediate agonist-independent phosphorylation of receptors and 
initiate heterologous desensitization. 
Cellular responses to SP that are mediated by the NKI-R rapidly 
desensitize. Thus, in 1953 Gaddum noted that the contractile 
response of guinea pig ileum to challenge with a high concentration 
of SP rapidly desensitized and gradually resensitized (Gaddum, 
1953). Recently, the molecular mechanisms of this desensitization 
have been explored. The C-tail and third intracellular loop of the 
NKI-R contain numerous serine and threonine residues that are 
potential phosphorylation sites for G-protein receptor kinases. 
There are at least six members of this kinase fiunily, which have the 
distinct feature of only phosphorylating agonist-occupied receptors. 
With regard to receptors for hormones and neurotransmitters, most 
attention has focused on GRK2 and GRK3. These kinases are also 
known as tJ-adrenergic receptor kinase 1 and 2 because their role in 
desensitization was originally defined for the f:l2-adrenergic recep­
tor. Both kinases phosphorylate the NKI-R in a reconstituted 
system (Kwatra et ai, 1993). The NKI-R was reconstituted in 
phospholipid vesicles with its G-protein Gqll• GRK 2 and 3, in the 
presence of SP, induced marked phosphorylation of this receptor, in 
a manner similar to that with which they phosphorylate the 
f:l2-adrenergic receptor in the presence of isoproterenol. The sites of 
phosphorylation of the NKI-R have yet to be defined, and 
phosphorylation of the NKI-R in intact cells has not been exam­
ined. Truncation of the NKI-R at position 338, however, which 
removes many potential phosphorylation sites in the C-tail, dimin­
ishes desensitization (Sasakawa et ai, 1994). 
By analogy with the f:l2-adrenergic receptor, the next phase of 
desensitization is probably interaction of the phosphorylated recep­
tor with tJ-arrestins. The arrestins are a family of proteins that 
interact with phosphorylated G-protein-coupled receptors and thus 
serve as functional co-factors for the GRKs. tJ-arrestins 1 and 2 are 
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probably most important for desensitization of the neuropeptide 
receptors. The phosphorylated NKI-R may bind to arrestins and 
uncouple from G-proteins because inositol pentakisphosphate, 
which disrupts the interactions of arrestins with receptors, attenu­
ates desensitization of the NKI-R (Sasakawa et ai, 1994). 
Further experiments are required to define the role of G-protein 
receptor kinases and arrestins in desensitization of the NK1-R. This 
will entail disruption of these proteins by use of inhibitors or 
expression of dominant negative mutants, with the expectation that 
these approaches will attenuate desensitization. Alternatively, these 
proteins could be overexpressed to enhance desensitization. Similar 
strategies have been used to study the f32-adrenergic receptor 
(Lefkowitz et ai, 1992; Lefkowitz, 1993). It will also be important 
to localize these proteins with the NK1-R to verify that they are 
co-localized and thus able to modulate receptor function. 
AGONIST-INDUCED RECEPTOR ENDOCYTOSIS 
The ability of cells to respond to hormones and neurotransmitters 
requires the presence of receptors that are appropriately located at 
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Figure 4. Localization of the NKI-R (left 
panels) and cyanine-3-1abeled (fluores­
cent) SP (right panels) in cultured myen­
teric neurons at various times after 
warming to 37°C. For localization of the 
NKl-R by immunofluorescence, neurons 
were incubated with 10 nM SP for 2 h at 4°C, 
washed, and incubated in SP-free medium at 
37°C for 0 min (A), 5 min (B), 30 min (C), or 
100 min (D). Neurons were fixed and incu­
bated with the NK1-R antibody and a Texas 
Red-labeled secondary antibody. For localiza­
tion of the ligand, neurons were incubated 
with 100 nM cyanine-3-SP-SP for 2 h at 4°C, 
washed, incubated in SP-free medium at 37°C 
for 0 min (E), 5 min (F), 10 min (G), or 100 
min (H), and fixed. � indicates internalization 
of the NK1-R and cyanine-3-SP from the 
plasma membrane to endosomes. Scale bar, 10 
/Lm. [Reprinted from Neuroscience Vol. 75. 
Endocytosis and recycling of neurokinin 1 re­
ceptors in enteric neurons, 1239-1254. Copy­
right 1996, with kind permission from Elsevier 
Science Ltd, The Boulevard. Langford Lane, 
Kidlington OX5 1GB, UK.] 
the plasma membrane where they can interact with high affinity 
with agonists in the extracellular fluid. Thus, the responsiveness of 
target cells is critically dependent on the subcellular distribution of 
receptors, and alterations in this distribution may contribute to 
regulation of cellular responses. Agonist-induced endocytosis of 
G-protein-coupled receptors is important in desensitization and 
resensitization of signaling. 
Endocytosis of the NK1-R has been examined in multiple cell 
types. We have extensively studied agonist-stimulated endocytosis 
of the NK1-R using receptor antibodies, fluorescently labeled SP, 
and confocal microscopy (Bowden et ai, 1994; Garland et ai, 1994; 
Grady et ai, 1995, 1996). SP stimulated NK1-R internalization in 
transfected epithelial cells, primary cultures of enteric neurons, and 
endothelial cells of post-capillary venules (Fig 4). In transfected 
epithelial cells and neurons, SP and the NK1-R internalized by a 
clathrin-mediated mechanism into vesicles that rapidly shed their 
clathrin coat. Both the peptide and its receptor then entered vesicles 
that also contained the transferrin receptor and are thus early 
endosomes. Endosomes congregated in a perinuclear region where 
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Figure 5. Effects of drugs on desensitization and resensitization of 
[CaH], responses in CHO-NKIR cells to two sequential exposures 
to SP. Cells were exposed to a 10 nM desensitizing dose of agonist or to 
carrier (control), washed after 1 min, and then exposed to a 10 nM test dose 
of agonist at various times after the desensitizing dose. Results are expressed 
as the percent response to the test dose of agonist when compared to the 
carrier-treated cells at each time point. PAO/BME, 80 ILM phenylarsine 
oxide, 5 IJ.M J3-mercaptoethanol; bafilomycin At, 1 ILM; okadaic acid, 50 
nM. Mean ::':: SE, n = 3 experiments, triplicate observations. *p < 0.05 
compared to carrier control. [Reproduced with permission from Garland et 
ai, 1996.] 
acidification induced dissociation of the ligand and its receptor and 
sorting into different pathways. SP was degraded in lysosomes, and 
the NK1-R appeared to recycle to the plasma membrane. In 
support of receptor recycling is the observation that recovery of the 
receptor and of agonist-binding sites at the cell surface was 
prevented by inhibitors of endosomal acidification, such as the 
vacuolar H+ -ATPase inhibitor bafilomycin A, both in cell lines and 
primary cultures of neurons. This treatment caused retention of the 
NK1-R within the cell and prevented degradation of SP. Recovery 
was unaffected, however, by inhibition of protein synthesis. Re­
ceptors for other neurotransmitters, such as the 132-adrenergic 
receptor and the gastrin-releasing peptide receptor, similarly inter­
nalize and recycle (von Zastrow and Kobilka, 1992; Grady et aI, 
1995). 
Endocytosis depletes the plasma membrane of high-affinity re­
ceptors that are available to interact with hydrophilic peptides in the 
extracellular fluid. Therefore, endocytosis may contribute to de­
sensitization of receptors. Several observations, however, indicate 
that this is not the case for many receptors. Thus, inhibitors of 
endocytosis do not impede desensitization of the 132-adrenergic 
receptor (Yu et aI, 1993). Similarly, we found that inhibition of 
endocytosis with phenylarsine oxide had no effect on desensitiza­
tion of the NK1-R to repeated application of SP (Fig 5) (Garland 
et aI, 1996). These observations with drugs, which may have 
nonspecific effects, are supported by observations with receptor 
mutants. Thus, a point mutation of the 132-adrenergic receptor, 
which prevents agonist-mediated receptor endocytosis, has no 
effect on receptor desensitization (Barak et aI, 1994). Together, 
these results indicate that internalization is not the principal mech­
anism of desensitization of these receptors. Rather, phosphoryla­
tion by GRKs and interaction with l3-arrestins are the primary 
mechanisms for desensitization of the 132-adrenergic and neurokinin 
receptors. 
Endocytosis is important, however, for resensitization of some 
receptors for hormones and neurotransmitters. Resensitization of 
the 132-adrenergic receptor is prevented by inhibition of endocytosis 
by drugs or receptor mutation (Yu et aI, 1993; Barak et aI, 1994). 
We found that resensitization of the NK1-R was also blocked by 
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endocytic inhibitors (Fig 5) (Garland et aI, 1996). These findings 
imply that processing of the internalized receptor is necessary for 
resensitization. This may include dissociation of the ligand in 
acidified endosomes, dephosphorylation of the receptor, dissocia­
tion of arrestins, and recycling of the receptor to the plasma 
membrane. SP dissociates from the NKI-R in acidified perinuclear 
endosomes, and we found that inhibitors of endosomal acidification 
such as bafilomycin A1 and monensin inhibited receptor recycling 
and also blocked resensitization (Fig 5) (Grady et aI, 1995; Garland 
et aI, 1996). If receptor phosphorylation and interaction with 
arrestins is the main mechanism of desensitization, resensitization 
may require dephosphorylation and dissociation of arrestins. Endo­
somes are enriched with phosphatase, and the 132-adrenergic recep­
tor in endosomes is less phosphorylated than at the plasma mem­
brane and does not resensitize if recycling is blocked. We found 
that the phosphatase inhibitor okadaic acid prevented resensitiza­
tion of the NK1-R, suggesting that receptor dephosphorylation is 
important (Fig 5) (Garland et aI, 1996). Detailed studies of recep­
tors in endosomes are hampered, however, by difficulties in 
endosomal purification. 
Endocytosis of receptors requires their interaction with proteins 
that are components of the endocytic machinery (Trowbridge et aI, 
1993). Receptor motifs that interact with the endocytic apparatus 
have not been adequately characterized. To identify domains of the 
NKI-R that are important for SP-mediated endocytosis, we mu­
tated the NKI-R and examined endocytosis using [125I]SP, fluo­
rescent SP, and receptor antibodies (Bohm et aI, 1997). SP induced 
rapid internalization of wild-type receptors that were targeted to 
perinuclear endosomes. Truncation of the C-tail at residues 324, 
342, and 354 reduced internalization up to 60% and caused 
retention of receptors at the cell surface and in superficial endo­
somes. Mutation of Y341 and Y349 in potential tyrosine-contain­
ing endocytic motifs of the C-tail also impaired internalization. A 
Y305A mutant within the putative NP:K., Y endocytic motif of the 
seventh transmembrane domain showed impaired signaling and was 
minimally expressed at the plasma membrane but was found in 
cytoplasmic vesicles even without exposure to agonist. In contrast, 
the Y305F mutant signaled normally and was normally expressed at 
the plasma membrane, but showed impaired internalization. Thus, 
we demonstrated that endocytosis of the NKI-R relies on several 
tyrosine-containing endocytic motifs in the C-tail and seventh 
transmembrane domain. 
CONCLUSIONS AND FUTURE DIRECTIONS 
Until recendy, most studies of regulation by peptides have focused 
on understanding the mechanisms that regulate hormone and 
neurotransmitter release. It is important, however, that we also 
understand mechanisms of signal attenuation, for these will govern 
the ability of cells to respond to peptide agonists. Multiple mech­
anisms contribute to this attenuation. Peptide degradation by cell 
surface enzymes is the first step, which serves to confine the effects 
of pep tides to a particular cell type or even to a limited region of the 
plasma membrane of individual cells. Thus, susceptibility to deg­
radation may determine the duration and extent of the biologic 
effects of peptides, and the ability of a peptide to regulate distant 
cells will require resistance to degradation. Once a peptide interacts 
with its receptors and induces a signal, however, the signal is rapidly 
attenuated by receptor desensitization. This is mediated by receptor 
phosphorylation and uncoupling from G-proteins. Resensitization 
requires internalization of the agonist-occupied receptors, dissoci­
ation of agonists in acidified endosomes, receptor dephosphoryla­
tion, and efficient recycling of receptors to the plasma membrane. 
Attenuation of signaling is important for it prevents the uncon­
trolled stimulation of cells, whereas resensitization is critical be­
cause it allows a cell or tissue to maintain its ability to respond to 
agonists over time. Defects in these mechanisms may result in the 
uncontrolled stimulation of cells, which may lead to disease. 
Defects in peptide degradation, which may result from down­
regulation of peptidases, result in elevated levels of pep tides in the 
extracellular fluid and uncontrolled stimulation. Abnormalities also 
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occur at the level of the receptor. For example, point mutations of 
the receptors for thyrotropin and luteinizing hormone-releasing 
hormone, which result in constitutive activity of the receptors in 
the absence of ligand, are associated with thyroid adenoma and a 
form of male precocious puberty. Desensitization may be important 
in disease states where there is continued secretion of an agonist, 
e.g., a peptide-secreting tumor. More than half of all medicines 
used today exert their elfects through signaling pathways that 
involve G-proteins. Thus, many commonly used drugs act by 
interfering with mechanisms that remove neurotransmitters from 
the extracellular space, or are themselves agonists or antagonists of 
G-protein-coupled receptors. Discovery of new ways in which 
these signaling pathways are modulated could help explain and 
perhaps counter the phenomenon of drug tolerance: the need for 
increasing doses to achieve a constant elfect. 
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